HK1092151A1 - Polymorphous forms of rifaximin as antibiotics - Google Patents

Polymorphous forms of rifaximin as antibiotics

Info

Publication number
HK1092151A1
HK1092151A1 HK06113864.0A HK06113864A HK1092151A1 HK 1092151 A1 HK1092151 A1 HK 1092151A1 HK 06113864 A HK06113864 A HK 06113864A HK 1092151 A1 HK1092151 A1 HK 1092151A1
Authority
HK
Hong Kong
Prior art keywords
rifaximin
antibiotics
polymorphous forms
polymorphous
forms
Prior art date
Application number
HK06113864.0A
Other languages
English (en)
Inventor
Giuseppe C Viscomi
Manuela Campana
Dario Braga
Donatella Confortini
Vincenzo Cannata
Denis Severini
Paolo Righi
Goffredo Rosini
Original Assignee
Alfa Wassermann Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33187382&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1092151(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alfa Wassermann Spa filed Critical Alfa Wassermann Spa
Priority to HK06113864.0A priority Critical patent/HK1092151A1/xx
Publication of HK1092151A1 publication Critical patent/HK1092151A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • H—ELECTRICITY
    • H05—ELECTRIC TECHNIQUES NOT OTHERWISE PROVIDED FOR
    • H05B—ELECTRIC HEATING; ELECTRIC LIGHT SOURCES NOT OTHERWISE PROVIDED FOR; CIRCUIT ARRANGEMENTS FOR ELECTRIC LIGHT SOURCES, IN GENERAL
    • H05B6/00—Heating by electric, magnetic or electromagnetic fields
    • H05B6/02—Induction heating
    • H05B6/10—Induction heating apparatus, other than furnaces, for specific applications
    • H05B6/12—Cooking devices
    • H05B6/1209—Cooking devices induction cooking plates or the like and devices to be used in combination with them
    • H05B6/1236—Cooking devices induction cooking plates or the like and devices to be used in combination with them adapted to induce current in a coil to supply power to a device and electrical heating devices powered in this way
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • H—ELECTRICITY
    • H05—ELECTRIC TECHNIQUES NOT OTHERWISE PROVIDED FOR
    • H05B—ELECTRIC HEATING; ELECTRIC LIGHT SOURCES NOT OTHERWISE PROVIDED FOR; CIRCUIT ARRANGEMENTS FOR ELECTRIC LIGHT SOURCES, IN GENERAL
    • H05B6/00—Heating by electric, magnetic or electromagnetic fields
    • H05B6/02—Induction heating
    • H05B6/10—Induction heating apparatus, other than furnaces, for specific applications
    • H05B6/12—Cooking devices
    • H05B6/1209—Cooking devices induction cooking plates or the like and devices to be used in combination with them
    • H05B6/1245—Cooking devices induction cooking plates or the like and devices to be used in combination with them with special coil arrangements
    • H05B6/1263—Cooking devices induction cooking plates or the like and devices to be used in combination with them with special coil arrangements using coil cooling arrangements

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Physics & Mathematics (AREA)
  • Electromagnetism (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
HK06113864.0A 2003-11-07 2005-08-04 Polymorphous forms of rifaximin as antibiotics HK1092151A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
HK06113864.0A HK1092151A1 (en) 2003-11-07 2005-08-04 Polymorphous forms of rifaximin as antibiotics

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IT002144A ITMI20032144A1 (it) 2003-11-07 2003-11-07 Forme polimorfe di rifaximina, processi per ottenerle e
HK06113864.0A HK1092151A1 (en) 2003-11-07 2005-08-04 Polymorphous forms of rifaximin as antibiotics
HK05106702A HK1073657A1 (en) 2003-11-07 2005-08-04 Polymorphous form of rifaximin as antibiotic

Publications (1)

Publication Number Publication Date
HK1092151A1 true HK1092151A1 (en) 2007-02-02

Family

ID=33187382

Family Applications (3)

Application Number Title Priority Date Filing Date
HK06113864.0A HK1092151A1 (en) 2003-11-07 2005-08-04 Polymorphous forms of rifaximin as antibiotics
HK06113863.1A HK1092150A1 (en) 2003-11-07 2005-08-04 Polymorphous forms of rifaximin as antibiotics
HK05106702A HK1073657A1 (en) 2003-11-07 2005-08-04 Polymorphous form of rifaximin as antibiotic

Family Applications After (2)

Application Number Title Priority Date Filing Date
HK06113863.1A HK1092150A1 (en) 2003-11-07 2005-08-04 Polymorphous forms of rifaximin as antibiotics
HK05106702A HK1073657A1 (en) 2003-11-07 2005-08-04 Polymorphous form of rifaximin as antibiotic

Country Status (38)

Country Link
US (5) US7045620B2 (de)
EP (6) EP1676848B1 (de)
JP (5) JP2005139161A (de)
KR (4) KR20050043589A (de)
CN (4) CN1613858A (de)
AR (3) AR043547A1 (de)
AT (3) ATE421965T1 (de)
AU (2) AU2004200964A1 (de)
BR (2) BRPI0402382A (de)
CA (2) CA2460384A1 (de)
CL (1) CL2004000498A1 (de)
CO (1) CO5560083A1 (de)
CY (3) CY1108017T1 (de)
DE (4) DE602004006367C5 (de)
DK (3) DK1557421T3 (de)
ES (3) ES2320160T4 (de)
HK (3) HK1092151A1 (de)
HR (2) HRP20040265A2 (de)
IL (2) IL160798A0 (de)
IT (1) ITMI20032144A1 (de)
JO (1) JO2470B1 (de)
MA (1) MA27069A1 (de)
MD (1) MD3653G8 (de)
ME (1) ME00424B (de)
MX (2) MXPA04002353A (de)
NO (1) NO334950B1 (de)
NZ (1) NZ531622A (de)
PL (3) PL1676848T3 (de)
PT (3) PT1676847E (de)
RS (4) RS20060168A (de)
RU (1) RU2270200C2 (de)
SI (3) SI1676847T1 (de)
TN (2) TNSN04044A1 (de)
TW (1) TWI285107B (de)
UA (1) UA86384C2 (de)
WO (1) WO2005044823A2 (de)
YU (1) YU24804A (de)
ZA (1) ZA200401948B (de)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7048906B2 (en) 1995-05-17 2006-05-23 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
US6861053B1 (en) * 1999-08-11 2005-03-01 Cedars-Sinai Medical Center Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
US7902206B2 (en) * 2003-11-07 2011-03-08 Alfa Wassermann, S.P.A. Polymorphic forms α, β and γ of rifaximin
US7906542B2 (en) * 2004-11-04 2011-03-15 Alfa Wassermann, S.P.A. Pharmaceutical compositions comprising polymorphic forms α, β, and γ of rifaximin
ITMI20032144A1 (it) * 2003-11-07 2005-05-08 Alfa Wassermann Spa Forme polimorfe di rifaximina, processi per ottenerle e
US20080262024A1 (en) * 2003-11-07 2008-10-23 Giuseppe Claudio Viscomi Rifaximin compositions and method of use
US7923553B2 (en) * 2003-11-07 2011-04-12 Alfa Wassermann, S.P.A. Processes for the production of polymorphic forms of rifaximin
ES2522895T3 (es) 2005-03-03 2014-11-19 Alfa Wassermann S.P.A. Nuevas formas polimorfas de rifaximina, procedimientos para su producción y uso de las mismas en preparados medicinales
ITBO20050123A1 (it) 2005-03-07 2005-06-06 Alfa Wassermann Spa Formulazioni farmaceutiche gastroresistenti contenenti rifaximina
AU2007281413B2 (en) 2006-08-02 2013-10-31 Christopher Jahraus Compositions and methods for the treatment of radiation proctosigmoiditis
ITMI20061692A1 (it) * 2006-09-05 2008-03-06 Alfa Wassermann Spa Uso di polioli per ottenere forme polimorfe stabili di rifaximina
NZ575550A (en) * 2006-09-22 2011-12-22 Cipla Ltd Rifaximin
US20080161337A1 (en) * 2007-01-03 2008-07-03 Leonard Weinstock Use of Rifaximin for the Treatment of Chronic Prostatitis
US20080159987A1 (en) * 2007-01-03 2008-07-03 Leonard Weinstock Use of Rifaximin for the Treatment of Restless Legs Syndrome
ITMI20071241A1 (it) * 2007-06-20 2008-12-21 Solmag S P A Processo per la preparazione di rifaximina amorfa e rifaximina amorfa cosi' ottenuta
PL2011486T5 (pl) * 2007-07-06 2016-09-30 Lupin Ltd Farmaceutyczne kompozycje rifaksyminy
AU2016203925B2 (en) * 2007-07-06 2016-10-20 Lupin Limited Pharmaceutical compositions of rifaximin
JP5755878B2 (ja) * 2007-07-06 2015-07-29 ルパン リミテッドＬｕｐｉｎ Ｌｉｍｉｔｅｄ リファキシミンの薬剤組成物
US7709634B2 (en) * 2007-09-20 2010-05-04 Apotex Pharmachem Inc. Amorphous form of rifaximin and processes for its preparation
MY158257A (en) * 2008-02-25 2016-09-30 Salix Pharmaceuticals Ltd Forms of rifaximin and uses thereof
US8486956B2 (en) * 2008-02-25 2013-07-16 Salix Pharmaceuticals, Ltd Forms of rifaximin and uses thereof
US11779571B2 (en) 2008-02-26 2023-10-10 Salix Pharmaceuticals, Inc. Methods for treating irritable bowel syndrome (IBS)
DK2252148T3 (da) * 2008-02-26 2019-05-06 Salix Pharmaceuticals Ltd Fremgangsmåder til behandling af irritabel tarmsyndrom
WO2009137672A1 (en) 2008-05-07 2009-11-12 Salix Pharmaceuticals, Ltd. Methods of treating bowel disease by administering a bowel cleanser and an antibiotic
DK2327407T3 (da) 2008-09-26 2014-08-25 Aska Pharm Co Ltd Profylaktisk og/eller terapeutisk middel til funktionelle gastrointestinale sygdomme
US20100317681A1 (en) * 2009-06-15 2010-12-16 Salix Pharmaceuticals, Ltd. Modulation of systemic exposure to rifaximin
PL2350096T3 (pl) 2008-10-02 2020-06-29 Salix Pharmaceuticals, Ltd. Sposoby leczenia encefalopatii wątrobowej
US7928115B2 (en) * 2008-10-02 2011-04-19 Salix Pharmaceuticals, Ltd. Methods of treating travelers diarrhea and hepatic encephalopathy
US20110035232A1 (en) 2008-10-02 2011-02-10 Salix Pharmaceuticals, Ltd. Methods of treating hepatic encephalopathy
KR101906177B1 (ko) 2008-12-10 2018-10-10 시플라 리미티드 리팍시민 복합체
IT1397617B1 (it) * 2009-04-20 2013-01-18 Alfa Wassermann Spa Nuovi derivati della rifamicina
CN102548408A (zh) * 2009-06-02 2012-07-04 萨利克斯药品有限公司 治疗肝性脑病的方法
EP2475392A4 (de) 2009-09-13 2013-01-09 Salix Pharmaceuticals Ltd Verfahren zur behandlung des reizdarmsyndroms
CN102665693A (zh) * 2009-10-27 2012-09-12 鲁平有限公司 利福昔明固体分散体
WO2011061748A1 (en) * 2009-11-19 2011-05-26 Strides Arcolab Limited Rifaximin premix
JP2013511570A (ja) 2009-11-23 2013-04-04 シプラ・リミテッド 局所用泡沫組成物
EP2401282B2 (de) † 2009-12-28 2017-01-04 Silvio Massimo Lavagna Verfahren zur herstellung von amorphem rifaximin
WO2011103246A1 (en) 2010-02-18 2011-08-25 Salix Pharmaceuticals, Ltd. Methods for treating infection
IT1398550B1 (it) 2010-03-05 2013-03-01 Alfa Wassermann Spa Formulazioni comprendenti rifaximina utili per ottenere un effetto prolungato nel tempo
NZ603590A (en) * 2010-06-03 2015-08-28 Salix Pharmaceuticals Ltd New forms of rifaximin and uses thereof
WO2011156897A2 (en) * 2010-06-16 2011-12-22 Apotex Pharmachem Inc. Polymorphic forms of rifaximin
SI2593463T1 (sl) 2010-07-12 2020-10-30 Salix Pharmaceuticals, Inc. Formulacije rifaksimina in njihove uporabe
WO2012035544A2 (en) 2010-09-13 2012-03-22 Sequent Scientific Ltd. A novel polymorphic form of rifaximin and process for its preparation
IT1403847B1 (it) * 2010-09-22 2013-11-08 Alfa Wassermann Spa Composizioni farmaceutiche comprendenti rifaximina e loro uso.
WO2012060675A1 (es) * 2010-11-05 2012-05-10 Interquim, S.A. De C.V. Proceso para la preparación de rifaximina amorfa
WO2012076832A1 (en) * 2010-12-09 2012-06-14 Cipla Limited Suppositories comprising rifaximin
AU2012214239B2 (en) * 2011-02-11 2016-06-30 Salix Pharmaceuticals, Ltd. Forms of Rifaximin and uses thereof
EP2705042A1 (de) 2011-05-02 2014-03-12 Ranbaxy Laboratories Limited Rifaximin-dimethylformamid-solvat
WO2012155981A1 (en) 2011-05-19 2012-11-22 Friulchem Spa New process for the synthesis of rifaximin and a new pseudo-crystalline form of rifaximin obtained thereby
ITMI20110890A1 (it) * 2011-05-19 2012-11-20 A M S A Anonima Materie Sint & Affini S P A Polimorfo di rifaximina e processo per la sua preparazione
ITBO20110461A1 (it) 2011-07-29 2013-01-30 Alfa Wassermann Spa Composizioni farmaceutiche comprendenti rifaximina, processi per la loro preparazione e loro uso nel trattamento di infezioni vaginali.
US20130184302A1 (en) * 2011-11-02 2013-07-18 Enoch Bortey Methods for treating irritable bowel syndrome (ibs) and infections
JP2013184902A (ja) * 2012-03-06 2013-09-19 Aska Pharmaceutical Co Ltd リファキシミン含有結晶
WO2013185211A1 (en) * 2012-06-13 2013-12-19 Apotex Pharmachem Inc. Polymorphic forms of rifaximin
ITBO20120368A1 (it) 2012-07-06 2014-01-07 Alfa Wassermann Spa Composizioni comprendenti rifaximina e amminoacidi, cristalli di rifaximina derivanti da tali composizioni e loro uso.
WO2014091432A1 (en) 2012-12-12 2014-06-19 Ranbaxy Laboratories Limited Pharmaceutical compositions of rifaximin
WO2014140995A2 (en) 2013-03-15 2014-09-18 Alfa Wassermann S.P.A. Method for diagnosing vaginal infections
US20160038468A1 (en) 2013-03-15 2016-02-11 Alfa Wassermann S.P.A. Rifaximin for use in the treating of vaginal infections
CN105324109A (zh) 2013-04-12 2016-02-10 意大利阿尔法韦士曼制药公司 Nsaid施用和相关的组合物、方法和系统
US9018225B1 (en) 2013-07-26 2015-04-28 Novel Laboratories Rifaximin crystalline forms and methods of preparation thereof
EP2927235B1 (de) * 2014-03-31 2017-02-08 Euticals S.P.A. Polymorphe Mischung von Rifaximin und ihre Verwendung zur Herstellung fester Formulierungen
CA2946101A1 (en) * 2014-04-19 2015-10-22 Granules India Limited An improved process for the preparation of rifamycin derivatives
EP3140313B1 (de) 2014-05-04 2020-02-26 Salix Pharmaceuticals, Inc. Ibs-mikrobiota und verwendungen davon
ES2810010T3 (es) 2014-05-12 2021-03-08 Alfasigma Spa Preparación y uso de la forma cristalina tau de rifaximina solvatada con DEGME
MX2016016458A (es) * 2014-06-30 2017-07-13 Salix Pharmaceuticals Inc Métodos para repetir tratamiento de síndrome del intestino irritable (ibs).
CN104083324B (zh) * 2014-07-10 2017-05-10 青岛动保国家工程技术研究中心有限公司 一种利福昔明的兽用悬乳剂及其制备方法和应用
EP2982764A1 (de) 2014-08-05 2016-02-10 ALFA WASSERMANN S.p.A. Identifizierung von Vaginalbakterien
CN104274391B (zh) * 2014-10-08 2017-02-01 哈尔滨坤盟医药科技有限公司 一种含利福昔明的药物制剂
WO2017021975A1 (en) * 2015-08-06 2017-02-09 Msn Laboratories Private Limited Process for the preparation of crystalline forms of rifaximin
EP3294270B1 (de) 2016-03-24 2018-09-12 Sandoz AG Pharmazeutische zusammensetzung mit rifaximin alpha und delta
HUE044432T2 (hu) 2016-03-24 2019-10-28 Sandoz Ag Rifaximin alfá-t tartalmazó, hosszan eltartható kompozíció
US9988398B2 (en) * 2016-06-07 2018-06-05 Cadila Healthcare Limited Crystalline form of rifaximin and process for its preparation
EP4137132A1 (de) 2016-09-30 2023-02-22 Salix Pharmaceuticals, Inc. Feste dispersionsformen von rifaximin
CN106632396B (zh) * 2017-01-06 2019-01-11 成都樵枫科技发展有限公司 γ晶型利福昔明的制备方法和用途
PL3416627T3 (pl) * 2017-04-26 2020-06-01 Sandoz Ag Doustna postać dawkowania zawierająca rifaksyminę w postaci beta
EP3645539B1 (de) 2017-06-26 2021-04-07 Biofer S.p.A. Pyrido-imidazo-rifamycinderivate als antibakterielle mittel
WO2020245214A1 (en) 2019-06-03 2020-12-10 Bausch Health Ireland Limited Use of methylnaltrexone and rifaximin for treatment of increased gut permeability or associated disorders
BR112022003500A2 (pt) 2019-09-24 2022-05-24 Bausch Health Ireland Ltd Formulações líquidas de rifaximina
WO2021191312A1 (en) 2020-03-24 2021-09-30 Bausch Health Ireland Limited Methods of treating covid-19 with rifaximin
WO2021229480A1 (en) * 2020-05-15 2021-11-18 Atra Pharmaceuticals Limited Polymorph of rifaximin, process for the preparation thereof and pharmaceutical composition containing rifaximin
CN116018133A (zh) 2020-06-26 2023-04-25 博士医疗爱尔兰有限公司 靶向释放利福昔明组合物
WO2022090490A1 (en) 2020-10-29 2022-05-05 Bausch Health Ireland Limited Rifaximin liquid formulations for use in the treatment of sickle cell disease

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4241785A (en) * 1978-07-24 1980-12-30 Peerless Of America, Inc. Heat exchangers and method of making same
IT1154655B (it) * 1980-05-22 1987-01-21 Alfa Farmaceutici Spa Derivati imidazo-rifamicinici metodi per la loro preparazione e loro uso come sostanza ad azione antibatterica
IT1199374B (it) * 1984-05-15 1988-12-30 Alfa Farmaceutici Spa Processo per la preparazione di pirido-imidazo-rifamicine
CA1215976A (en) 1984-05-15 1986-12-30 Vincenzo Cannata New process for the synthesis of imidazo rifamycins
IT1199413B (it) 1984-09-26 1988-12-30 Alfa Farmaceutici Spa Processo per la preparazione di pirido-imidazo-rifamicine
GB8816620D0 (en) * 1988-07-13 1988-08-17 Lepetit Spa Rifapentine hydrohalides
EP0536197B1 (de) * 1990-06-29 1995-07-26 GRUPPO LEPETIT S.p.A. Reine kristalline form von rifapentin
US20020048610A1 (en) * 2000-01-07 2002-04-25 Cima Michael J. High-throughput formation, identification, and analysis of diverse solid-forms
UA75365C2 (en) * 2000-08-16 2006-04-17 Bristol Myers Squibb Co Epothilone analog polymorph modifications, a method for obtaining thereof (variants), a pharmaceutical composition based thereon
CA2426393C (en) * 2000-10-31 2012-05-29 Ciba Specialty Chemicals Holding Inc. Crystalline forms of venlafaxine hydrochloride
IL156055A0 (en) * 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
ITMI20032144A1 (it) * 2003-11-07 2005-05-08 Alfa Wassermann Spa Forme polimorfe di rifaximina, processi per ottenerle e
US20050262269A1 (en) 2004-05-20 2005-11-24 Pike Jimmy D System and method for information handling system PCI express advanced switching
ES2522895T3 (es) 2005-03-03 2014-11-19 Alfa Wassermann S.P.A. Nuevas formas polimorfas de rifaximina, procedimientos para su producción y uso de las mismas en preparados medicinales
NZ575550A (en) * 2006-09-22 2011-12-22 Cipla Ltd Rifaximin
WO2008115572A1 (en) 2007-03-21 2008-09-25 Theraquest Biosciences, Inc. Methods and compositions of nsaids
ITMI20071241A1 (it) 2007-06-20 2008-12-21 Solmag S P A Processo per la preparazione di rifaximina amorfa e rifaximina amorfa cosi' ottenuta
PL2011486T5 (pl) 2007-07-06 2016-09-30 Lupin Ltd Farmaceutyczne kompozycje rifaksyminy
JP5755878B2 (ja) * 2007-07-06 2015-07-29 ルパン リミテッドＬｕｐｉｎ Ｌｉｍｉｔｅｄ リファキシミンの薬剤組成物
US7709634B2 (en) * 2007-09-20 2010-05-04 Apotex Pharmachem Inc. Amorphous form of rifaximin and processes for its preparation
WO2009047801A1 (en) 2007-10-10 2009-04-16 Lupin Limited Therapeutic combinations and compositions for the treatment of gastrointestinal disorders
MY158257A (en) 2008-02-25 2016-09-30 Salix Pharmaceuticals Ltd Forms of rifaximin and uses thereof

Also Published As

Publication number Publication date
MD3653G8 (ro) 2016-08-31
US7915275B2 (en) 2011-03-29
US20080132530A1 (en) 2008-06-05
AR043547A1 (es) 2005-08-03
RU2004108953A (ru) 2005-10-27
DE602004006367D1 (de) 2007-06-21
KR20070113327A (ko) 2007-11-28
KR100883216B1 (ko) 2009-02-13
JP5635376B2 (ja) 2014-12-03
EP1682556A2 (de) 2006-07-26
BRPI0407149A8 (pt) 2019-01-15
MXPA06002644A (es) 2006-06-06
EP2208730A1 (de) 2010-07-21
ES2320160T3 (es) 2009-05-19
HRP20040265A2 (en) 2004-12-31
AR081991A2 (es) 2012-10-31
ES2320160T4 (es) 2011-03-09
IL174271A0 (en) 2006-08-01
RS54571B1 (en) 2016-06-30
US20120059023A1 (en) 2012-03-08
ME00424B (me) 2011-10-10
PL1557421T3 (pl) 2007-08-31
HK1073657A1 (en) 2005-10-14
CN101260114A (zh) 2008-09-10
ES2244364T1 (es) 2005-12-16
PT1557421E (pt) 2007-07-31
CN1613858A (zh) 2005-05-11
UA86384C2 (uk) 2009-04-27
ES2320161T3 (es) 2009-05-19
IL160798A0 (en) 2004-08-31
EP1676847A1 (de) 2006-07-05
PT1676848E (pt) 2009-04-09
JP2014177500A (ja) 2014-09-25
PL1676847T3 (pl) 2009-07-31
EP1676847B1 (de) 2009-01-28
CN101260115A (zh) 2008-09-10
KR20060110737A (ko) 2006-10-25
EP1557421B1 (de) 2007-05-09
CN1886408A (zh) 2006-12-27
MD20060080A (en) 2006-11-30
CO5560083A1 (es) 2005-09-30
NZ531622A (en) 2004-10-29
TNSN06069A1 (en) 2007-10-03
HRP20060093B1 (hr) 2015-12-18
CY1108017T1 (el) 2013-09-04
CN101260114B (zh) 2012-11-28
AR081992A2 (es) 2012-10-31
TNSN04044A1 (en) 2006-06-01
CY1108964T1 (el) 2014-07-02
KR20070113326A (ko) 2007-11-28
CN1886408B (zh) 2010-06-09
EP1557421A1 (de) 2005-07-27
ITMI20032144A1 (it) 2005-05-08
JP5199576B2 (ja) 2013-05-15
ATE421965T1 (de) 2009-02-15
TW200515913A (en) 2005-05-16
US8173801B2 (en) 2012-05-08
US7045620B2 (en) 2006-05-16
CA2460384A1 (en) 2005-05-07
RS20150291A1 (en) 2015-10-30
US20110160449A1 (en) 2011-06-30
SI1557421T1 (sl) 2007-08-31
ATE421966T1 (de) 2009-02-15
CL2004000498A1 (es) 2005-03-11
DK1676847T3 (da) 2009-05-11
IL174271A (en) 2010-12-30
DK1557421T3 (da) 2007-09-17
WO2005044823A2 (en) 2005-05-19
JP2011046738A (ja) 2011-03-10
BRPI0402382A (pt) 2005-06-28
ES2244364T3 (es) 2007-12-01
JP2007509904A (ja) 2007-04-19
SI1676848T1 (sl) 2009-06-30
ZA200401948B (en) 2004-04-29
AU2004287601B8 (en) 2009-03-05
CA2538546A1 (en) 2005-05-19
DE602004006367C5 (de) 2019-04-04
RU2270200C2 (ru) 2006-02-20
DE04005541T1 (de) 2005-12-29
BRPI0407149A (pt) 2006-02-07
PT1676847E (pt) 2009-04-09
DK1676848T3 (da) 2009-05-11
EP1676848A1 (de) 2006-07-05
SI1676847T1 (sl) 2009-06-30
CY1108909T1 (el) 2014-07-02
HK1092150A1 (en) 2007-02-02
MXPA04002353A (es) 2005-05-11
US8404704B2 (en) 2013-03-26
YU24804A (sh) 2006-08-17
NO20061110L (no) 2006-04-19
AU2004287601B2 (en) 2009-02-26
AU2004200964A1 (en) 2005-05-26
JP2011057698A (ja) 2011-03-24
AU2004287601A1 (en) 2005-05-19
DE602004019298D1 (de) 2009-03-19
JO2470B1 (en) 2009-01-20
KR100855084B1 (ko) 2008-08-29
US20050272754A1 (en) 2005-12-08
ATE361927T1 (de) 2007-06-15
KR20050043589A (ko) 2005-05-11
RS54568B1 (en) 2016-06-30
US20050101598A1 (en) 2005-05-12
EP2210893A1 (de) 2010-07-28
RS20060168A (en) 2008-09-29
PL1676848T3 (pl) 2009-07-31
WO2005044823A3 (en) 2005-10-27
RS54569B1 (en) 2016-06-30
MA27069A1 (fr) 2004-12-20
CA2538546C (en) 2011-04-19
MD3653F2 (en) 2008-07-31
RS20150292A1 (en) 2015-10-30
NO334950B1 (no) 2014-08-04
DE602004006367T2 (de) 2007-09-06
HRP20060093A2 (en) 2006-05-31
CN101260115B (zh) 2011-11-23
JP2005139161A (ja) 2005-06-02
KR100867751B1 (ko) 2008-11-10
DE602004019296D1 (de) 2009-03-19
EP1676848B1 (de) 2009-01-28
TWI285107B (en) 2007-08-11

Similar Documents

Publication Publication Date Title
HK1092150A1 (en) Polymorphous forms of rifaximin as antibiotics
HK1093483A1 (en) Polymorphic form of n-
IL169905A0 (en) Novel 2-pyridinecarboxamide derivatives
EP1596860A4 (de) Neue verbindungen
EP1648885A4 (de) Neue verbindungen
EP1487414A4 (de) Antibiotische zusammensetzung
EP1620101A4 (de) Polymorphe von cabergolin
ZA200507475B (en) Derivatives of azithromycin
GB0312368D0 (en) Novel ureido- and amido-pyrazolone derivatives
GB0315629D0 (en) New uses for antibiotic
EP1793812A4 (de) Antibiotische verbindung
GB0302431D0 (en) Novel compounds
GB0302546D0 (en) Novel compounds
EP1756034A4 (de) Antibiotische verbindung
EP1635834A4 (de) Neue verbindungen
GB0302008D0 (en) Antibiotic derivatives
PL378080A1 (pl) Sposób wytwarzania K-252A
GB0303767D0 (en) Gentamycin antibiotics
GB0303874D0 (en) Novel antibacterial compounds
TW568246U (en) Gasifying kiln
PL114147U1 (en) Interior decoration element
GB0301591D0 (en) Novel compounds
GB0301593D0 (en) Novel compounds
GB0300484D0 (en) Novel compounds
GB0301480D0 (en) Novel compounds

Legal Events

Date Code Title Description
PE Patent expired

Effective date: 20240308